Table 1.

SUZ12 expression in human EOCs and its correlation with clinicopathological variables or expression of EZH2 and Ki67

SUZ12 protein expression
Patient characteristicsLow (n)High (n)Total (n)High (%)p
Normal tissue
 Normal ovary epithelial2873520.0%<0.001a
 Fallopian tube1321513.3%<0.001b
Epithelial ovarian cancer279011776.9%
 Type I7172470.8%
  Low-grade serous415
  Mucinous123
  Low grade Endometrioid257
  Clear cell088
  Other011
 Type II20739378.5%
  High-grade serous167187
  Other (high-grade endometrioid)426
Age
 ≤5511334475.0%
 >5516577378.1%0.701
Laterality
 Left8253375.8%
 Right5172277.3%
 Bilaterality14476177.1%0.988
 Undetermined011
Ki67c
 0%–10%1692536.0%
 10%–40%6182475.0%
 40%–100%5636892.7%<0.001
EZH2 expressiond
 Low19224153.7%
 High8687689.5%<0.001
Tumor stage
 Stage 1/210203066.7%
 Stage 3/417708780.5%0.122
  • aCompared with epithelial ovarian cancer, P < 0.001.

  • bCompared with serous epithelial ovarian cancer, P < 0.001.

  • cSpearman's Rank Order Correlation also showed SUZ12 positively correlated with Ki67 (P < 0.001), and rs is 0.465.

  • dSpearman's Rank Order Correlation also showed SUZ12 positively correlated with EZH2 (P < 0.001), and rs is 0.515.